Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions

Core Insights - Aptar Digital Health has entered into an enterprise agreement with Biogen to operate and develop digital health solutions for neurological and rare diseases, with Biogen transferring ownership of select digital health solutions to Aptar [1][3] - The collaboration will enable Aptar to provide comprehensive capabilities including product management, design, development, maintenance of software applications, secured cloud hosting, and customer support [1][3] Group 1: Digital Health Solutions - Biogen has successfully launched several digital health solutions that have supported hundreds of thousands of patients across over 15 countries [2] - The initial solutions transitioning to Aptar's operation include Cleo™/Aby™, a digital care companion app for multiple sclerosis, and Physio.me, a digital exercise companion for patients with neuromuscular disorders [2] Group 2: Future Collaborations - Biogen and Aptar plan to collaborate on developing new digital health solutions for conditions such as spinal muscular atrophy, Friedreich's ataxia, and lupus in selected countries [3] - The agreement signifies Aptar Digital Health's expansion into neurology and immunology, which are strategic therapeutic areas for the company [3] Group 3: Company Overview - Aptar is a global leader in drug and consumer product dosing, dispensing, and protection technologies, serving markets including pharmaceuticals, beauty, food, and personal care [4] - Aptar Digital Health focuses on creating end-to-end solutions to enhance patient experiences, leveraging a holistic ecosystem of digital interventions [4]